Maraviroc and NeuroAIDS Pathogenesis

Inclusion Criteria: * Documentation of HIV-1 infection by an FDA approved test at any time prior to study entry. * Receipt of ARV medication uninterrupted for \> 1 year leading up to the screening period; brief interruptions for toxicity purposes will be evaluated on a case by case basis and may be allowed * Screening plasma HIV RNA \< 50 copies/ml within 3 months of entry * Willingness for both males and females of childbearing potential to utilize 2 effective contraception methods (2 separate forms, one of which must be an effective barrier method), be non-heterosexually active or have a an exclusive vasectomized partner from screening throughout the duration of the study treatment and for 30 days following the last dose of study drugs. * Age between 18 to 70 years. * Ability and willingness to provide written informed consent Mild to moderate cognitive impairment with global neuropsychological (NP) test (NPZglobal) score of \< -0.5 OR a neurocognitive abnormality (\< -0.5) in at least one cognitive domain known to be typically affected by HIV Exclusion Criteria: * Currently receiving or having used a CCR5 antagonist as part of an antiretroviral regimen within 6 months of study entry * Plasma HIV RNA \> 100 copies/ml at any time within 6 months of study entry * History of HIV-2 * Diagnosis of cirrhosis * Active or inadequately treated tuberculosis (TB) infection, or inadequate treatment for a positive purified protein derivative (PPD) test. Adequate treatment is defined …